Regulatory Freelancing: Rare Disease Group Hopes To Shape FDA Guidance
Executive Summary
EveryLife Foundation is working on a white paper that it hopes will inform FDA’s guidance clarifying accelerated approval and fast track pathways, which is mandated in FDASIA.
You may also be interested in...
FDA Accelerated Approval For Rare Diseases Again Under Congressional Pressure
Letter being circulated by Rep. Bilirakis states the agency’s draft expedited approval guidance does not provide clarity for rare disease sponsors to use accelerated approval.
Biomarker Approvals At Pre-IND Stage Requested For Orphan Drugs
Updated draft white paper on expanding use of accelerated approval suggests FDA approve the use of biomarkers as surrogate endpoints in the pre-IND stage, which could enhance sponsors’ abilities to raise funds for trials and manufacturing.
“Complete Response” Letters Might Include Benefit-Risk Framework Discussion
FDA official says idea could be helpful; meanwhile, sponsors and others remain concerned about the framework’s undefined decision-making methods.